ERBB2 and breast cancer: In addition, we found that Ano1 overexpression was associated with longer OS in HER2-negative, but not HER2-postive, patients following tamoxifen treatment, suggesting that HER2 signaling may be involved in the role of Ano1 in breast cancer development.